Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma

Abstract Introduction Nivolumab plus ipilimumab (NIVO + IPI) and pembrolizumab plus axitinib (PEM + AXI) are first-line (1L) treatments for advanced or metastatic renal cell carcinoma (aRCC), although the long-term trends in their associated real-world healthcare costs are not well defined. We compa...

Description complète

Détails bibliographiques

Auteurs principaux:	Ella Xiaoyan Du, Keith A. Betts, Travis Wang, Sophie A. Kitchen, Xuanhao He, Xin Yin, Sarah B. Guttenplan, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2024-08-01
Collection:	Oncology and Therapy
Sujets:	Advanced or metastatic renal cell carcinoma Healthcare costs Nivolumab plus ipilimumab Pembrolizumab plus axitinib Real world
Accès en ligne:	https://doi.org/10.1007/s40487-024-00297-0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!